+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer



The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer



Lung Cancer 37(3): 303-309



This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P = 0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P = 0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P = 0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P < 0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047665814

Download citation: RISBibTeXText

PMID: 12234700

DOI: 10.1016/s0169-5002(02)00103-4


Related references

Phase II study of postoperative adjuvant therapy in patients with completely resected stage II and IIIA non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics 51(3 Suppl. 1): 23-24, 2001

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. Cancer Radiotherapie 5(2): 195-196, 2001

Phase II study of postoperative adjuvant therapy in patients with completely resected stage II and IIIA non-small cell lung cancer (RTOG 97-05). International Journal of Radiation Oncology*biology*physics 51(3-Supp-S1): 23-24, 2001

Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer 42(1): 79-86, 2003

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. Journal of Clinical Oncology 35(25): 2960-2974, 2017

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. New England Journal of Medicine 343(17): 1217-1222, 2000

Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer. Minerva Chirurgica 68(2): 169-174, 2013

The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Management and Research 5: 327-336, 2013

Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. British Journal of Cancer 95(7): 817-821, 2006

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. Journal of the National Cancer Institute 95(19): 1453-1461, 2003

S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stage II/IIIA non-small-cell lung cancer. Molecular and Clinical Oncology 8(1): 73-79, 2018

A prospective randomized study of adjuvant chemotherapy in completely resected stage IIIA-N2 non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 9(5): 434-438, 2006

Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 34(1): 29-36, 2001

Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 64(3): 192-196, 2009

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet. Oncology 7(9): 719-727, 2006